v
Search
Advanced

Publications > Journals > Most Viewed Articles

Results per page:
v
Original Article Open Access
Zhandong Lin, Yue Shi, Mengjiao Sun, Jiawei Cui, Dandan Zhao, Yaoyao Mao, Congyue Zhang, Ying Zhang, Qianqian Zheng, Yukai Chen, Shaoya Li, Yuemin Nan
Published online January 22, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 5675
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2025.00592
Abstract
Liver fibrosis is characterized by the excessive deposition of extracellular matrix, a process primarily driven by activated hepatic stellate cells (HSCs), and currently lacks effective [...] Read more.

Liver fibrosis is characterized by the excessive deposition of extracellular matrix, a process primarily driven by activated hepatic stellate cells (HSCs), and currently lacks effective therapy. Cathepsin K (CTSK) exhibits context-dependent roles across organ systems in fibrosis, but its function in liver fibrosis is unclear. This study aimed to investigate the role and underlying mechanisms of CTSK during liver fibrosis.

CTSK expression was analyzed in human fibrotic liver samples via transcriptomic analysis and confirmed in murine fibrosis models. The function of CTSK was investigated in both primary HSCs and LX-2 cells by assessing its effects on cell activation, proliferation, apoptosis, and the underlying signaling pathways following CTSK overexpression. The therapeutic potential was evaluated using an adeno-associated virus serotype 8 to overexpress CTSK in two etiologically distinct murine fibrosis models.

CTSK was upregulated in activated HSCs and fibrotic livers. Furthermore, we discovered that it mediates a negative feedback loop to inhibit the TGF-β/Smad pathway via Smad7/Smurf2-dependent TGF-β receptor-I degradation, thereby suppressing HSC activation and proliferation. CTSK also induced mitochondrial apoptosis through Bax/Bcl-2 imbalance and caspase-3 activation. Together, these actions contribute to the anti-fibrotic effect of CTSK. Notably, adeno-associated virus serotype 8-mediated CTSK overexpression attenuated liver fibrosis across multiple murine models.

Our study demonstrates that elevated CTSK functions as an endogenous protective factor that attenuates liver fibrosis. CTSK mediates negative feedback inhibition of the TGF-β pathway while concurrently promoting the mitochondrial apoptosis pathway. The dual anti-fibrotic mechanisms identify CTSK as a promising therapeutic target for liver fibrosis.

Full article
Original Article Open Access
Xiaoliang Jin, Jing Zhao, Yuenian Chen, Li Xu, Ming Cheng, Ting Ye, Haifeng Jin, Liang Huang, Yue Hu, Haibiao Bao, Bin Lyu
Published online December 19, 2025
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 5633
Cancer Screening and Prevention. doi:10.14218/CSP.2025.00025
Abstract
Accumulating evidence indicates that fecal syndecan-2 (SDC2) methylation is a promising biomarker for early detection of colorectal cancer. This study aimed to investigate the diagnostic [...] Read more.

Accumulating evidence indicates that fecal syndecan-2 (SDC2) methylation is a promising biomarker for early detection of colorectal cancer. This study aimed to investigate the diagnostic efficacy of fecal SDC2 methylation testing for adenomas and evaluate the risk stratification efficacy of the Asia-Pacific Colorectal Screening Scoring (APCS) combined with SDC2 methylation status.

This was a prospective, multicenter diagnostic study. Adult participants with no history of colonoscopy within the past three years were enrolled. Demographic data were collected, and APCS scores were evaluated. All participants underwent fecal SDC2 methylation testing and colonoscopy. Colonoscopy outcomes and pathological results of any polyps served as reference standards. The fecal SDC2 methylation test and reference standard assessments were conducted in a blinded manner. The APCS-SDC2 scoring system was developed by integrating fecal SDC2 methylation results with APCS scores, and its efficacy was assessed.

In total, 985 participants were enrolled, among whom 62 (6.3%) tested positive for fecal SDC2 methylation. The sensitivity and specificity of fecal SDC2 methylation in detecting advanced adenomas were 31.3% (95% confidence interval (CI): 21.6–42.7%) and 96.1% (95% CI: 94.6–97.2%), respectively. The APCS-SDC2 scoring system yielded an area under the curve of 0.7032 (95% CI: 0.5869–0.8195) for advanced adenomas in the validation set. For advanced adenoma screening, the specificity of the APCS-SDC2 score was higher than that of the APCS score (96.3% vs. 66.7%; P < 0.001).

A positive fecal SDC2 methylation test indicated a higher risk of advanced adenoma, and colonoscopy should be prioritized. The APCS-SDC2 scoring system may improve risk stratification performance, particularly by increasing specificity.

Full article
Original Article Open Access
Lishan Shen, Xiaowen Luo, Xiaorui Su, Xiang Zhou, Fengyun Zou, Shuangshuang Zhong, Yayin Deng, Boya Yin, Zhicheng Yao, Ruomi Guo
Published online May 11, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 5589
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2025.00709
Abstract
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, underscoring the need for effective therapies. Although miR-125b-5p shows therapeutic potential, [...] Read more.

Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, underscoring the need for effective therapies. Although miR-125b-5p shows therapeutic potential, its efficacy in metabolic dysfunction-associated steatotic liver disease (MASLD)-related HCC and the underlying mechanisms remain unclear. In this study, we aimed to develop a magnetic resonance imaging (MRI)-trackable miR-125b-5p-engineered MSC platform for HCC therapy and to determine whether MASLD attenuates its antitumor efficacy through metabolic reprogramming.

Bone marrow mesenchymal stem cells (MSCs) were genetically engineered to coexpress miR-125b-5p (a therapeutic gene) and ferritin heavy chain (Fth; a MRI reporter gene), enabling sustained delivery and real-time tracking. Orthotopic HCC models with or without MASLD were established to evaluate therapeutic outcomes. In vivo MRI, histological analyses, and bioinformatics approaches were used to assess efficacy and mechanisms.

Transplantation of miR-125b-5p-Fth-MSCs significantly suppressed HCC growth in vivo over an extended period. However, MASLD attenuated this therapeutic effect. Mechanistically, miR-125b-5p directly targeted hexokinase 2 (HK2), inhibiting HCC proliferation and migration through suppression of the PI3K/AKT/mTOR pathway. Fatty acid-induced lipotoxicity upregulated HK2 expression and counteracted the antitumor effects of miR-125b-5p.

Multigene-modified MSCs enable effective, MRI-monitored HCC therapy. MASLD diminishes the efficacy of miR-125b-5p through HK2 upregulation. These findings establish a multimodal theranostic framework for HCC and provide mechanistic insights into MASLD-associated therapeutic resistance.

Full article
Editorial Open Access
Hong Li, Yuyong Tan
Published online May 11, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 5566
Journal of Translational Gastroenterology. doi:10.14218/JTG.2026.00013
Review Article Open Access
Qiyun Sheng, Yuting Wang, Min Xu, Cuie Cheng, Zhengqing Xue, Lu Chen, Yiming Du, Mingwei Ni, Qi Zhang, Jiajun Jiang, Qin Lu
Published online March 29, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 5547
Cancer Screening and Prevention. doi:10.14218/CSP.2026.00002
Abstract
N6-methyladenosine (m6A), the most prevalent internal RNA modification in eukaryotic cells, is a dynamic regulator of RNA metabolism and cancer biology. In colorectal cancer (CRC), [...] Read more.

N6-methyladenosine (m6A), the most prevalent internal RNA modification in eukaryotic cells, is a dynamic regulator of RNA metabolism and cancer biology. In colorectal cancer (CRC), dysregulated m6A reshapes transcriptomic programs that control tumor growth, metastasis, immune evasion, and therapeutic resistance. However, the context-dependent functions of individual m6A regulators remain incompletely defined, the integration of m6A with canonical oncogenic signaling remains incomplete, and its role in metabolic reprogramming lacks a systematic overview. This review aims to integrate current evidence on m6A regulatory machinery in CRC, clarify its coordination with oncogenic signaling and metabolic pathways, and highlight emerging translational implications. The key players regulating m6A in CRC progression are m6A “writers”, including methyltransferase-like 3 and methyltransferase-like 14; m6A “erasers”, including fat mass and obesity-associated protein and AlkB homolog 5; and m6A “readers”, including the YTH m6A RNA-binding protein family and the insulin-like growth factor 2 mRNA-binding protein family. m6A modification coordinates key oncogenic pathways, including Wnt/β-catenin, PI3K/Akt, MAPK, and p53 signaling. Moreover, m6A-dependent regulation of metabolic enzymes such as hexokinase 2, pyruvate kinase M2, and fatty acid synthase promotes the reprogramming of glucose, amino acid, and lipid metabolism, linking epitranscriptomic control to bioenergetic adaptation. We also discuss context-dependent and paradoxical functions of m6A regulators and advances in m6A-targeted therapies. In conclusion, m6A modification functions as a central regulatory hub in CRC by integrating signaling networks and metabolic pathways. Deeper mechanistic insights into spatiotemporal m6A regulation may accelerate the development of biomarkers and targeted therapies for precision CRC management.

Full article
Original Article Open Access
Najwa Suliman Muhammed, Jayashri Sanjay Thorat, Azeza S. Guma, Prerna Pravin Pitrubhakta, Saurav Bhiku Marathe, Ibrahim Fouad, Alsadek Hassan Bogzil, Randa Mahmoud Mohamed, Idress Hamad Attitalla, Adam I. Elzagheid
Published online May 15, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 5489
Journal of Exploratory Research in Pharmacology. doi:10.14218/JERP.2025.00046
Abstract
Microbial resistance and oxidative stress are two significant health issues associated with chronic illnesses and therapy failures. The antioxidant and antibacterial properties [...] Read more.

Microbial resistance and oxidative stress are two significant health issues associated with chronic illnesses and therapy failures. The antioxidant and antibacterial properties of Euphorbia cuneata Vahl. aerial component extracts made with various polarity solvents were assessed in this work.

Disc diffusion and minimum inhibitory concentration (MIC) tests were used to evaluate the 1,1-diphenyl-2-picrylhydrazyl radical scavenging activity, total phenolic and flavonoid contents, and antimicrobial activity of n-hexane, toluene, ethanolic, and aqueous extracts against specific ESKAPE pathogens (Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans). High-performance liquid chromatography and gas chromatography-mass spectrometry were used to further characterize the most active extract.

Compared to the aqueous (IC₅₀ = 51.61 µg/mL), toluene (IC₅₀ = 30.57 µg/mL), and n-hexane (IC₅₀ = 128.15 µg/mL) extracts, the ethanolic extract demonstrated the greatest 1,1-diphenyl-2-picrylhydrazyl radical scavenging activity (97.90 ± 0.8%; IC₅₀ = 28.52 µg/mL). Additionally, it has the highest levels of flavonoids (40.5 ± 1.5 mg luteolin equivalents/g) and phenolic (80.0 ± 0.2 mg gallic acid equivalents/g). While gas chromatography-mass spectrometry found methyl 12-hydroxy-9-octadecenoate (44.39%) as the main volatile molecule, high-performance liquid chromatography analysis identified caffeic acid, pyrogallol, rutin, and 7-hydroxyflavone as important ingredients. The ethanolic extract showed antifungal activity against C. albicans (MIC = 6.25 mg/mL) and moderate antibacterial activity with the lowest MIC values against S. aureus (450 µg/mL) and E. coli (500 µg/mL).

The ethanolic extract of Euphorbia cuneata demonstrated potent in vitro antioxidant activity and moderate antimicrobial effects, primarily attributable to its high phenolic and flavonoid content. These results support its potential as a natural source of bioactive compounds for further development.

Full article
Illuminating and Instructive Clinical Case Open Access
Yuhong Suo, Lixue Xu, Xinyan Zhao, Yu Wang, Fuliang He, Jidong Jia
Published online May 14, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 5487
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00044
Abstract
Hepatic myelopathy, a rare neurological complication of decompensated chronic liver disease, profoundly impairs quality of life. While liver transplantation represents the only [...] Read more.

Hepatic myelopathy, a rare neurological complication of decompensated chronic liver disease, profoundly impairs quality of life. While liver transplantation represents the only curative treatment for hepatic myelopathy, we report a case in which progressive and severe spastic paraparesis was markedly improved following embolization of a paraspinal vein shunt.

Full article
Original Article Open Access
Xu Cao, Xiwei Lu, Qingwei Li, Jiali Lu, Xiaoping Song, Yinglun Han, Chunwen Pu, Yue Pang
Published online March 20, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 5469
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2025.00654
Abstract
Given the lack of efficient biomarkers for hepatocellular carcinoma (HCC) diagnosis, this study aimed to develop an HCC diagnostic strategy based on serum protein glycosylation [...] Read more.

Given the lack of efficient biomarkers for hepatocellular carcinoma (HCC) diagnosis, this study aimed to develop an HCC diagnostic strategy based on serum protein glycosylation signatures. We characterized differential N-glycosylation patterns of serum IgG to differentiate HCC from healthy controls and liver cirrhosis, and elucidated the molecular mechanisms driving aberrant Neu5Gc elevation in HCC to provide a theoretical basis for clinical application and differential diagnosis of HCC.

LIP-ELISA was applied to quantify serum Neu5Gc in 6,768 healthy individuals for baseline establishment. IgG was purified and subsequently analyzed by RPLC-MS/MS for glycosylation profiling in HCC and healthy samples. Bioinformatic analysis of CMAH and related gene clusters modulating Neu5Gc synthesis was conducted.

In a cohort of 1,114 participants, the LIP-ELISA platform achieved 80.21% sensitivity, 96.01% specificity, and 92.46% accuracy for primary HCC diagnosis. Serum IgG from HCC patients displayed multi-branched N-glycans modified with core fucose and Neu5Gc. Key molecules involved in glycan modification were identified, enabling the development of multiplexed gene detection for HCC, LC, and chronic hepatitis B. In vitro assays confirmed hypoxia-induced sialic acid accumulation in HCC cells. Meanwhile, CMAH-knockout mouse experiments verified that an exogenous high-sialic-acid diet compensates for endogenous Neu5Gc synthesis deficiency, revealing a dietary-mediated compensatory mechanism for Neu5Gc elevation.

This study established an LIP-ELISA-based clinical diagnostic platform combining AFP and Neu5Gc, defined sialic acid–modified glycan structures, and preliminarily identified regulators of Neu5Gc biosynthesis, providing novel insights for HCC diagnosis and mechanism research.

Full article
Review Article Open Access
Xiaoling Su, Aidiya Yimamu, Sheng Tu, Mengxuan Hao, Haiyang Bi, Ting Liu, Minmin Zhang, Xianbin Xu, Xia Yu, Zhenyu Shan, Jifang Sheng, Yu Shi, Zeyu Sun
Published online February 10, 2026
[ Html ] [ PDF ] [ Google Scholar ] [ Cite ]  Views: 5449
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2025.00502
Abstract
End-stage liver disease (ESLD) is characterized by a dramatic deterioration of liver function, frequently accompanied by systemic inflammatory storms and multiple organ failures. [...] Read more.

End-stage liver disease (ESLD) is characterized by a dramatic deterioration of liver function, frequently accompanied by systemic inflammatory storms and multiple organ failures. Central to the onset and progression of ESLD, systemic inflammation arises from complex interactions among various inflammatory signaling molecules and immune cells within and beyond the liver. As key inflammatory modulatory molecules, bioactive oxylipins have been increasingly recognized for their complex molecular mechanisms implicated in various diseases. This review aims to summarize recent findings regarding the molecular and immunological mechanisms through which oxylipins contribute to the development of liver injury and failure, with emphasis on both substantial intrahepatic and extrahepatic immune and inflammatory dysregulation associated with ESLD. Furthermore, this review discusses the translational potential of targeting oxylipins for clinical diagnosis, prognosis, and therapeutic intervention in ESLD.

Full article
Opinion Open Access
PrevPage 12 of 36 12…111213…3536Next
Back to Top